NVNOTook a little nibble on NVNO. Chat doesnt look to bad with price at the bottom of the range and making a nice W. The book also look pretty clean with a low share count finviz.com
Pharmaceuticals
Healthcare is still in a bull market - be longAt the start of 2022, healthcare stocks have gotten killed, especially anything that was a winner in the past 1-2 years. A lot of people are getting rather bearish, but they shouldn't be. The fundamentals favor healthcare still in many ways, and momentum is still rather strong. We already got the breakout in healthcare stocks, and we just got the retest, which was enough to scare a lot of people out. Now is a great entry for a long position, coming out of a short consolidation into a potential new bull phase.
Excellent opportunity in DivislabDIVISLAB have taken support and forming pole and flag . Going to break channel and start up move. Targets are mentioned, must comment if have any suggestion. NSE:DIVISLAB
GDRX Heading to <$20 before reversal.GDRX heading to <$20. From there should start reversal. Based on quarterly result may do some consolidation.
Would take ~6-9 months to reclaim $40.
If interested look out for an entry around ~$18.
Buying Moderna HereBuying Moderna here, may be printing a double bottom on weekly. They arent going to let this pandemic go away so banking on more vaccines and more fun for a few more years at least. It is still WAY up from a few years ago so setting tight stops. Not advise.
CWBR Upside PotentialCWBR closed 2 months ago a $15.0 Million Public Offering of Common Stock and Warrants at $0.72, so this is a safe upside in my opinion if you want to enter now.
On the other hand, Cantor Fitzgerald brokerage has a $2.5 price target for it.
52 Week Range 0.34 - 2.27 Just bounced from its lowest support.
ACRX Daily Long Double Bottom Bullish Long TermACRX has reached the lowest price @.46 a share, it has also double bottomed on the daily, the daily candle is bullish .. Looking to ride this buy for a long term.
Going to ride it up to the red resistance trendline, if it becomes support it should reach $2 to $4. Happy New Year..
Down 90% in 2 days on a 100% Buy Rated CompanyThe most volume this stock has ever seen has been in the last two days when institutions dumped it
just days ago it had a $150 price target and was trading at $80
now it's trading at $10?
This is a crazy bargain, Robinhood even let's you buy this on margin which is crazy
MRK has a lot of headline potential from hereHeadline Potential
Merck has three drugs currently under priority FDA review, one of them a Covid-19 drug:
Molnupiravir, an antiviral for Covid-19 which has received a positive opinion from the advisory board and which Merck's CEO says should work against any variant
Vaxneuvance, a pneumococcal vaccine
Lynparza, a breast cancer drug
Merck also continues to make strong headway with Keytruda, an immunotherapy, which recently picked up another approval in Japan.
All of this means that Merck has a lot of headline potential in coming weeks, especially at a time when a new Covid-19 variant is spreading across the world. There's quite a bit of options activity in Merck today as traders place bets ahead of the news.
Technicals and Sentiment
Merck is currently near support from a long-term trend line and from the 200-day EMA. It has 26% upside to the average analyst price target and a bullish put/call ratio of .43. It has an average analyst rating of 9.3/10, which is very high. It gets an above average ESG score of 2.25/3.
Value
S&P Global gives Merck's fundamentals an average score of 90/100. IIt's currently trading -1.4 standard deviations below where it usually trades in relation to its major moving averages. Forward dividend yield is about 3.7%, forward P/E just over 11, forward P/S about 3.4. The price to free cash flow ratio is fairly high, at over 20, but that has to be interpreted in light of the other multiples. estimate that Merck has about 18% upside to its average price multiple of the last 3 years. Its earnings outlook is highly positive; I score its growth forecast a 5/6.
VRTX Long Chance on ChannelNASDAQ:VRTX had an ongoing negative Trend since July 2020. It broke the negative Trend 2 days ago.
For me its a very good chance and low price for VRTX.
strong up move with good volume crossing the negative trend
crossed EMA200 and MA200 on daily chart and also on weeky chart
still above EMA200 and MA200 on monthly chart
still in positive trend since 2008
good position in the market
good cashflow for the next years, even if products are failing
Morepen Lab - Looks promising for a buy due to multiple reasons Long due to multiple reasons
1. Trendline breakout
2. High volumes at breakout
3. RSI above 50 shows good relative strength
4. Pharma sector, mostly bullish at the moment
5. High risk to reward ration
Disclaimer: for learning purposes only!
FENC Analysis - Dip Buy0.786 can be seen as a previous point of resistance
now that price has moved higher than this level, it will be seen as a point of support for the breakdown of the rising wedge , a pattern that is commonly bearish (as you can see on the chart)
Pharmaceutical companies are possibly hot right now, due to the emergence of the new COVID variant.
Buy the Dip.
AcelRx Pharmaceuticals Price TargetsACRX AcelRx Pharmaceuticals is a specialty pharmaceutical company that focuses on the development and commercialization of therapies for the treatment of acute pain.
52 Week Range 0.65 - 2.94
Sitting at all time low now.
HC Wainwright has a 5usd price target for it.
My take profits are:
1: $0.95
2: $1.23
Stop loss: $0.57
Sequent scientificDouble bottom with RSI divergence, expect 13% upside in short term
Reasons:
1. double bottom
2. RSI divergence
3. Health pharma sector showing reversal signs
Note: for learning purposes
TMBR Timber Pharmaceuticals Upside PotentialTMBR Timber Pharmaceuticals had a recent public offering price of $0.64 per share of common stock and accompanying common warrant. The warrants have an exercise price of $0.70 per share.
The price is now 0.47usd
There is a strong upside potential short term!
Price Target 1: $0.85
Price Target 2: $1.37
Stop loss: $0.41
Looking forward to read your opinion about it.
MRNAWe took a short on MRNA in the high 300's or so and now Moderna is in the mid 200's.
I'm looking for potential gaps to be filled on Moderna to the upside before any further move to the downside.
Possiblity is still there for further downside, although this one may try to get a dead cat bounce in here.
Targets :
280
340
226 LIS..
Torrent Pharma ReversalThe stock has reached lower trendline and may undergo a reversal rally. Trade is supported by brokerage calls and Supports Nearby.
Risk Reward Ratio - 4:1
SL is placed below support zone & the lower trendline. The target is placed near resistance.
Gland Pharma Reversal TradeThe stock has reached lower trendline and may undergo a reversal rally. Trade is supported by brokerage calls and Supports Nearby.
Risk Reward Ratio - 3:1
SL is placed below support zone & the lower trendline. The target is placed near resistance.
TNXPTonix Pharmaceuticals
• Falling Wedge
• Bullish Deep Crab Harmonic Pattern
• Price Hit The Demand Zone
• 1st Higher Low
• Possible Trend Reversal From A Long
Downtrend
• Long-term HODL
• Earnings Report 5th November
• New Lab Acquired Recently
Biotech primed for a move higher?This one is almost pure intuition. We're in pharmaceuticals earnings season now. Seagen reports after market today. A bunch of other large holdings of XBI report on November 3-4, and a bunch more on November 8. Bonds and tech stocks have made a breakout move upward, and small caps look primed. (XBI is full of small and micro caps.) XBI has had a long consolidation here, and I really like the price action on it today. A lot of other sector funds have had mid-day pullbacks, but XBI has maintained its steady upward slope. It has poked above the 20-day EMA. My guess is that this will be green again tomorrow, so I've rolled the dice on a call expiring October 29. I'm also looking for continuation the next two weeks, with a first target of about 131.75.
OPTIlooks like the 5 down are about finished. Would want to see an ABC correction 1st then 5 up impulsive move B4 I could make any targets.
$ZNTL: Oncology MomentumZNTL broke 80 again today and is displaying a strong monthly momentum chart. IBB regaining 160 hopefully will signal at least a moderate health care push that could push ZNTL into the 90s and beyond. Good luck traders!
AVDLLooks like a push to the 618 fib retracement might be up next. If we have an impulsive 5 up incoming the chart should look like this IMO.
